Ethics of Surrogate Advertising: Celebrity Endorsement and Moral Complicity
IssueAugust 2026
PaperGS Paper 4
SubjectEthics and Ethical Crisis
Read time5 min
Context
The Maharashtra Food and Drug Administration's action in August 2026 against celebrities endorsing a cardamom brand suspected of functioning as surrogate advertising for tobacco products raises a question that regulation has long circled without settling: what a person of influence owes to those who are influenced by them, and whether formal legality discharges that obligation.
The Core Ethical Tension
The Legal Fiction and the Actual Message: surrogate advertising works by advertising a permitted product that shares a brand identity with a prohibited one. Every element of the advertisement is legal in itself; the meaning it conveys is not. The gap between what is said and what is communicated is the entire mechanism, and it is deliberate. An endorser who claims to be advertising cardamom is relying on a description that everyone involved — the brand, the agency, the regulator and the audience — understands to be untrue in effect.
Influence Creates Obligation: the reason a celebrity is paid a premium is precisely that their endorsement transfers trust from the person to the product. That transfer is the service being purchased. It is incoherent to accept payment for the transfer of trust and simultaneously deny responsibility for what the trust is used to sell.
Vulnerability of the Audience: tobacco initiation is concentrated in adolescence, and aspirational identification with a celebrity is strongest in exactly that group. The harm is therefore not evenly distributed across a consenting adult audience; it falls hardest on those least equipped to discount it.
Key Ethical Concepts and Applications
Moral Complicity and Degrees of Participation: ethical theory distinguishes principal wrongdoing from facilitation, but does not treat facilitation as blameless. The endorser does not manufacture or sell the product, but supplies an essential input — credibility — without which the campaign does not function. Complicity is graded by contribution, knowledge and availability of alternatives, and on all three the well-informed, freely-choosing, highly-paid celebrity endorser scores high.
Kant's Second Formulation: treating humanity always as an end and never merely as a means condemns an arrangement in which an audience's trust in a public figure is deliberately converted into a commercial instrument aimed at their own harm. The audience is being used, and their trust is the mechanism of use.
Utilitarian Accounting Done Honestly: a defender might argue that adults make free choices and the aggregate harm is speculative. An honest utilitarian calculation includes the epidemiological cost of tobacco use in India — a leading cause of preventable death and a major driver of oral cancer — set against the private commercial gain of a small number of parties. The calculation does not survive contact with the actual numbers.
Professional Ethics and the Standard of Reasonable Inquiry: professions impose a duty to inquire proportionate to the risk of the activity. An endorser signing a contract for a brand that shares its identity with a tobacco product cannot claim ignorance of a fact available to any member of the public. Wilful blindness has never been a recognised defence in professional ethics.
Corporate Responsibility and the Ethics of Design: the brand's conduct is the more serious wrong, because surrogate advertising is not an incidental effect but a designed circumvention. An organisation that constructs its compliance strategy around the letter of a rule while defeating its purpose has not complied; it has evaded, and has additionally externalised the reputational risk of that evasion onto the endorser.
Regulatory Ethics and the Limits of Rules: the episode also illustrates why rule-based regulation alone is insufficient against a determined counterparty. Every precisely drafted prohibition creates a precisely drafted workaround. Principle-based regulation — prohibiting communications whose effect is to promote a banned product, whatever their form — asks the regulator to make judgements, which is harder but is the only approach that closes the gap.
Institutional Challenges
The Cigarettes and Other Tobacco Products Act, 2003 prohibits direct tobacco advertising, and the Consumer Protection Act, 2019 introduced liability for misleading endorsements, yet enforcement against surrogate campaigns remains episodic and State-led rather than systematic.
The Advertising Standards Council of India is a self-regulatory body whose determinations lack the force of law, so the primary industry mechanism has limited deterrent effect.
Penalties are frequently small relative to endorsement fees and campaign returns, so a violation can be rationally treated as a cost of doing business.
Proving surrogacy requires establishing intent from circumstantial evidence — brand identity, media spend, product availability — which is evidentially demanding and slows enforcement.
Way Forward
Adopt a principle-based test that asks whether the effect of a communication is to promote a prohibited product, rather than requiring proof that the advertisement mentions it.
Set penalties as a multiple of campaign expenditure and endorsement fee, so that violation ceases to be commercially rational.
Require endorsers to conduct and record documented due diligence on brand ownership and product portfolio before signing, converting an ethical expectation into a professional standard.
Restrict brand-extension advertising where the extension product's sales are trivial relative to its advertising spend — an objective, auditable indicator of surrogacy.
Give the self-regulatory body statutory backing so its determinations carry consequences.
Conclusion
Surrogate advertising is a case where nothing illegal need occur for something plainly wrong to happen, which is exactly the terrain ethics is for. The endorser's defence — that the contract was for cardamom — is true as a description of the document and false as a description of the act. Public influence is not a neutral asset to be monetised without regard to use; the obligation it carries is the price of the trust that gives it value.